Mizuho Reiterates Outperform Rating on WAVE Life Sciences (WVE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
March 10, 2025 3:25 PM EDTJones Trading analyst Catherine Novack reiterated a Buy rating and $20.00 price target on WAVE Life Sciences (NASDAQ: WVE)
The analyst comments "What's new: We saw the first gene editing in AATD from Beam Therapeutics (BEAM, Roy, Buy, $34 PT) (press release). Initial results look positive, and it's... More
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
March 10, 2025 12:59 PM EDTJones Trading analyst Soumit Roy upgraded Beam Therapeutics Inc (NASDAQ: BEAM) from Hold to Buy with a price target of $34.00.
The analyst comments "Model changes: We are raising our POS for AATD to 35% from 15%, increasing our adjusted peak sales to ~$1.9BN in 2036, upgrading our rating to Buy from Hold and a PT of $34. BEAM's in vivo edited AATD data mark an important step for the gene editing space, where effective editing levels were observed. Liver biopsy data in the future would accurately quantify the percent editing, but management mentioned that likely >50%... More
